Cardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company. The Company develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.
Código de la empresaCDIO
Nombre de la empresaCardio Diagnostics Holdings Inc
Fecha de salida a bolsaNov 23, 2021
Fundada en2021
Director ejecutivoDr. Meeshanthini V. (Meesha) Dogan, Ph.D.
Número de empleados13
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 23
Dirección311 W. Superior Street
CiudadCHICAGO
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal60645
Teléfono18552269991
Sitio Web
Código de la empresaCDIO
Fecha de salida a bolsaNov 23, 2021
Fundada en2021
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos